Advertisement

Association Between Cannabis and Psychosis: Epidemiologic Evidence

      Abstract

      Associations between cannabis use and psychotic outcomes are consistently reported, but establishing causality from observational designs can be problematic. We review the evidence from longitudinal studies that have examined this relationship and discuss the epidemiologic evidence for and against interpreting the findings as causal. We also review the evidence identifying groups at particularly high risk of developing psychosis from using cannabis. Overall, evidence from epidemiologic studies provides strong enough evidence to warrant a public health message that cannabis use can increase the risk of psychotic disorders. However, further studies are required to determine the magnitude of this effect, to determine the effect of different strains of cannabis on risk, and to identify high-risk groups particularly susceptible to the effects of cannabis on psychosis. We also discuss complementary epidemiologic methods that can help address these questions.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • D’Souza D.C.
        • Perry E.
        • MacDougall L.
        • Ammerman Y.
        • Cooper T.
        • Wu Y.T.
        • et al.
        The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: Implications for psychosis.
        Neuropsychopharmacology. 2004; 29: 1558-1572
        • Iskedjian M.
        • Bereza B.
        • Gordon A.
        • Piwko C.
        • Einarson T.R.
        Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain.
        Curr Med Res Opin. 2007; 23: 17-24
        • Arendt M.
        • Rosenberg R.
        • Foldager L.
        • Perto G.
        • Munk-Jorgensen P.
        Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: Follow-up study of 535 incident cases.
        Br J Psychiatry. 2005; 187: 510-515
        • Hall W.
        • Degenhardt L.
        Cannabis use and psychosis: A review of clinical and epidemiological evidence.
        Aust N Z J Psychiatry. 2000; 34: 26-34
        • Regier D.A.
        • Farmer M.E.
        • Rae D.S.
        • Locke B.Z.
        • Keith S.J.
        • Judd L.L.
        • Goodwin F.K.
        Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study.
        JAMA. 1990; 264: 2511-2518
        • Semple D.M.
        • McIntosh A.M.
        • Lawrie S.M.
        Cannabis as a risk factor for psychosis: Systematic review.
        J Psychopharmacol. 2005; 19: 187-194
        • Ferdinand R.F.
        • Sondeijker F.
        • van der Ende J.
        • Selten J.P.
        • Huizink A.
        • Verhulst F.C.
        Cannabis use predicts future psychotic symptoms, and vice versa.
        Addiction. 2005; 100: 612-618
        • Hides L.
        • Lubman D.I.
        • Buckby J.
        • Yuen H.P.
        • Cosgrave E.
        • Baker K.
        • Yung A.R.
        The association between early cannabis use and psychotic-like experiences in a community adolescent sample.
        Schizophr Res. 2009; 112: 130-135
        • Miettunen J.
        • Tormanen S.
        • Murray G.K.
        • Jones P.B.
        • Maki P.
        • Ebeling H.
        • et al.
        Association of cannabis use with prodromal symptoms of psychosis in adolescence.
        Br J Psychiatry. 2008; 192: 470-471
        • Moore T.H.
        • Zammit S.
        • Lingford-Hughes A.
        • Barnes T.R.
        • Jones P.B.
        • Burke M.
        • Lewis G.
        Cannabis use and risk of psychotic or affective mental health outcomes: A systematic review.
        Lancet. 2007; 370: 319-328
        • Andreasson S.
        • Allebeck P.
        • Engstrom A.
        • Rydberg U.
        Cannabis and schizophrenia. A longitudinal study of Swedish conscripts.
        Lancet. 1987; 2: 1483-1486
        • Zammit S.
        • Allebeck P.
        • Andreasson S.
        • Lundberg I.
        • Lewis G.
        Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: Historical cohort study.
        BMJ. 2002; 325: 1199
        • Arseneault L.
        • Cannon M.
        • Poulton R.
        • Murray R.
        • Caspi A.
        • Moffitt T.E.
        Cannabis use in adolescence and risk for adult psychosis: Longitudinal prospective study.
        BMJ. 2002; 325: 1212-1213
        • van Os J.
        • Bak M.
        • Hanssen M.
        • Bijl R.V.
        • de Graaf R.
        • Verdoux H.
        Cannabis use and psychosis: A longitudinal population-based study.
        Am J Epidemiol. 2002; 156: 319-327
        • Kuepper R.
        • van Os J.
        • Lieb R.
        • Wittchen H.U.
        • Hofler M.
        • Henquet C.
        Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study.
        Br Med J. 2011; 342: d738
        • Callaghan R.C.
        • Cunningham J.K.
        • Allebeck P.
        • Arenovich T.
        • Sajeev G.
        • Remington G.
        • et al.
        Methamphetamine use and schizophrenia: A population-based cohort study in California.
        Am J Psychiatry. 2012; 169: 389-396
        • Fergusson D.M.
        • Horwood L.J.
        • Ridder E.M.
        Tests of causal linkages between cannabis use and psychotic symptoms.
        Addiction. 2005; 100: 354-366
        • Fergusson D.M.
        • Horwood L.J.
        • Swain-Campbell N.R.
        Cannabis dependence and psychotic symptoms in young people.
        Psychol Med. 2003; 33: 15-21
        • Henquet C.
        • Krabbendam L.
        • Spauwen J.
        • Kaplan C.
        • Lieb R.
        • Wittchen H.U.
        • van Os J.
        Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people.
        BMJ. 2005; 330: 11
        • Tien A.Y.
        • Anthony J.C.
        Epidemiological analysis of alcohol and drug use as risk factors for psychotic experiences.
        J Nerv Ment Dis. 1990; 178: 473-480
        • Wiles N.J.
        • Zammit S.
        • Bebbington P.
        • Singleton N.
        • Meltzer H.
        • Lewis G.
        Self-reported psychotic symptoms in the general population: Results from the longitudinal study of the British National Psychiatric Morbidity Survey.
        Br J Psychiatry. 2006; 188: 519-526
        • Rossler W.
        • Hengartner M.P.
        • Angst J.
        • Ajdacic-Gross V.
        Linking substance use with symptoms of subclinical psychosis in a community cohort over 30 years.
        Addiction. 2012; 107: 1174-1184
        • Gage S.H.
        • Hickman M.
        • Heron J.
        • Munafo M.
        • Lewis G.
        • Macleod J.
        • Zammit S.
        Associations of cannabis and cigarette use with psychotic experiences at age 18: Findings from the Avon Longitudinal Study of Parents and Children.
        Psychol Med. 2014; 44: 3435-3444
        • Power R.A.
        • Verweij K.J.
        • Zuhair M.
        • Montgomery G.W.
        • Henders A.K.
        • Heath A.C.
        • et al.
        Genetic predisposition to schizophrenia associated with increased use of cannabis.
        Mol Psychiatry. 2014; 19: 1201-1204
        • McGrath J.
        • Welham J.
        • Scott J.
        • Varghese D.
        • Degenhardt L.
        • Hayatbakhsh M.R.
        • et al.
        Association between cannabis use and psychosis-related outcomes using sibling pair analysis in a cohort of young adults.
        Arch Gen Psychiatry. 2010; 67: 440-447
        • Giordano G.N.
        • Ohlsson H.
        • Sundquist K.
        • Sundquist J.
        • Kendler K.S.
        The association between cannabis abuse and subsequent schizophrenia: A Swedish national co-relative control study.
        Psychol Med. 2015; 45: 407-414
        • Morgan C.J.
        • Curran H.V.
        Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis.
        Br J Psychiatry. 2008; 192: 306-307
        • Morgan C.J.
        • Gardener C.
        • Schafer G.
        • Swan S.
        • Demarchi C.
        • Freeman T.P.
        • et al.
        Subchronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being.
        Psychol Med. 2012; 42: 391-400
        • Iseger T.A.
        • Bossong M.G.
        A systematic review of the antipsychotic properties of cannabidiol in humans.
        Schizophr Res. 2015; 162: 153-161
        • Allott K.
        • Chanen A.
        • Yuen H.P.
        Attrition bias in longitudinal research involving adolescent psychiatric outpatients.
        J Nerv Ment Dis. 2006; 194: 958-961
        • Fischer E.H.
        • Dornelas E.A.
        • Goethe J.W.
        Characteristics of people lost to attrition in psychiatric follow-up studies.
        J Nerv Ment Dis. 2001; 189: 49-55
        • Rothman K.
        • Greenland S.
        • Lash T.L.
        Modern Epidemiology.
        3rd ed. Lippincott Williams & Wilkins, Philadelphia2008
        • Rubino T.
        • Parolaro D.
        Long lasting consequences of cannabis exposure in adolescence.
        Mol Cell Endocrinol. 2008; 286: S108-S113
        • Trezza V.
        • Cuomo V.
        • Vanderschuren L.J.
        Cannabis and the developing brain: Insights from behavior.
        Eur J Pharmacol. 2008; 585: 441-452
        • Chadwick B.
        • Miller M.L.
        • Hurd Y.L.
        Cannabis use during adolescent development: Susceptibility to psychiatric illness.
        Front Psychiatry. 2013; 4: 129
        • Caspi A.
        • Moffitt T.E.
        • Cannon M.
        • McClay J.
        • Murray R.
        • Harrington H.
        • et al.
        Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: Longitudinal evidence of a gene X environment interaction.
        Biol Psychiatry. 2005; 57: 1117-1127
        • Zammit S.
        • Owen M.J.
        • Lewis G.
        Misconceptions about gene-environment interactions in psychiatry.
        Evid Based Ment Health. 2010; 13: 65-68
        • Zammit S.
        • Wiles N.
        • Lewis G.
        The study of gene environment interactions in psychiatry: Limited gains at a substantial cost?.
        Psychol Med. 2010; 40: 711-716
        • van Winkel R.
        • Genetic Risk and Outcome of Psychosis (GROUP) Investigators
        Family-based analysis of genetic variation underlying psychosis-inducing effects of cannabis: Sibling analysis and proband follow-up.
        Arch Gen Psychiatry. 2011; 68: 148-157
        • Di Forti M.
        • Iyegbe C.
        • Sallis H.
        • Kolliakou A.
        • Falcone M.A.
        • Paparelli A.
        • et al.
        Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users.
        Biol Psychiatry. 2012; 72: 811-816
        • Duncan L.E.
        • Keller M.C.
        A critical review of the first 10 years of candidate gene-by-environment interaction research in psychiatry.
        Am J Psychiatry. 2011; 168: 1041-1049
        • Cougnard A.
        • Marcelis M.
        • Myin-Germeys I.
        • De Graaf R.
        • Vollebergh W.
        • Krabbendam L.
        • et al.
        Does normal developmental expression of psychosis combine with environmental risk to cause persistence of psychosis? A psychosis proneness-persistence model.
        Psychol Med. 2007; 37: 513-527
        • Harley M.
        • Kelleher I.
        • Clarke M.
        • Lynch F.
        • Arseneault L.
        • Connor D.
        • et al.
        Cannabis use and childhood trauma interact additively to increase the risk of psychotic symptoms in adolescence.
        Psychol Med. 2010; 40: 1627-1634
        • Houston J.E.
        • Murphy J.
        • Adamson G.
        • Stringer M.
        • Shevlin M.
        Childhood sexual abuse, early cannabis use, and psychosis: Testing an interaction model based on the National Comorbidity Survey.
        Schizophr Bull. 2008; 34: 580-585
        • Greenland S.
        • Lash T.L.
        • Rothman K.J.
        Concepts of Interaction In Modern Epidemiology.
        Lippincott Williams and Wilkins, Philadelphia2008
        • Zammit S.
        • Lewis G.
        • Dalman C.
        • Allebeck P.
        Examining interactions between risk factors for psychosis.
        Br J Psychiatry. 2010; 197: 207-211
        • Englund A.
        • Morrison P.D.
        • Nottage J.
        • Hague D.
        • Kane F.
        • Bonaccorso S.
        • et al.
        Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment.
        J Psychopharmacol. 2013; 27: 19-27
        • Di Forti M.
        • Marconi A.
        • Carra E.
        • Fraietta S.
        • Trotta A.
        • Bonomo M.
        • et al.
        Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: A case-control study.
        Lancet Psychiatry. 2015; 2: 233-238
        • Gage S.H.
        • Munafo M.R.
        • MacLeod J.
        • Hickman M.
        • Davey Smith G.
        Cannabis and psychosis: A problem of skunk, or extremes?.
        Lancet Psychiatry. 2015; 2: 380
        • Hardwick S.
        • King L.
        Home Office Cannabis Potency Study 2008.
        in: Office H. Home Office Cannabis Potency Study 2008. Home Office Scientific Development Branch, St Albans, UK2008
        • Mehmedic Z.
        • Chandra S.
        • Slade D.
        • Denham H.
        • Foster S.
        • Patel A.S.
        • et al.
        Potency trends of Delta9-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008.
        J Forensic Sci. 2010; 55: 1209-1217
        • King L.
        • Carpentier C.
        • Griffiths P.
        EMCDDA Insights: An overview of cannabis potency in Europe.
        European Monitoring Centre for Drugs and Drug Addiction, Villa Louvigny, Luxembourg2004
        • Frisher M.
        • Crome I.
        • Macleod J.
        • Millson D.
        • Croft P.
        Substance misuse and psychiatric illness: Prospective observational study using the general practice research database.
        J Epidemiol Community Health. 2005; 59: 847-850
        • van Amsterdam J.
        • Brunt T.
        • van den Brink W.
        The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects.
        J Psychopharmacol. 2015; 29: 254-263
        • Kuepper R.
        • Morrison P.D.
        • van Os J.
        • Murray R.M.
        • Kenis G.
        • Henquet C.
        Does dopamine mediate the psychosis-inducing effects of cannabis? A review and integration of findings across disciplines.
        Schizophr Res. 2010; 121: 107-117
        • Price C.
        • Hemmingsson T.
        • Lewis G.
        • Zammit S.
        • Allebeck P.
        Cannabis and suicide: Longitudinal study.
        Br J Psychiatry. 2009; 195: 492-497
        • Gage S.H.
        • Hickman M.
        • Heron J.
        • Munafo M.R.
        • Lewis G.
        • MacLeod J.
        • Zammit S.
        Association of cannabis and cigarette use with depression and anxiety at age 18: Findings from the Avon Longitudinal Study of Parents and Children.
        PLoS One. 2015; 10: e0122896
        • Ajdacic-Gross V.
        • Landolt K.
        • Angst J.
        • Gamma A.
        • Merikangas K.R.
        • Gutzwiller F.
        • Rössler W.
        Adult versus adolescent onset of smoking: How are mood disorders and other risk factors involved?.
        Addiction. 2009; 104: 1411-1419
        • Boydell J.
        • Van Os J.
        • Lambri M.
        • Castle D.
        • Allardyce J.
        • McCreadie R.G.
        • Murray R.M.
        Incidence of schizophrenia in south-east London between 1965 and 1997.
        Br J Psychiatry. 2003; 182: 45-49
        • Breslau J.
        • Aguilar-Gaxiola S.
        • Kendler K.S.
        • Su M.
        • Williams D.
        • Kessler R.C.
        Specifying race-ethnic differences in risk for psychiatric disorder in a USA national sample.
        Psychol Med. 2006; 36: 57-68
        • Frisher M.
        • Crome I.
        • Martino O.
        • Croft P.
        Assessing the impact of cannabis use on trends in diagnosed schizophrenia in the United Kingdom from 1996 to 2005.
        Schizophr Res. 2009; 113: 123-128
        • Davey Smith G.
        • Ebrahim S.
        Data dredging, bias, or confounding.
        BMJ. 2002; 325: 1437-1438
        • Meier M.H.
        • Caspi A.
        • Ambler A.
        • Harrington H.
        • Houts R.
        • Keefe R.S.
        • et al.
        Persistent cannabis users show neuropsychological decline from childhood to midlife.
        Proc Natl Acad Sci U S A. 2012; 109: E2657-E2664
        • Gage S.H.
        • Munafo M.
        • Davey Smith G.
        Causal inference in developmental origins of health and disease (DOHaD) research (in press).
        Annu Rev Psychol. 2016; 67: 567-585
        • Brion M.J.
        • Lawlor D.A.
        • Matijasevich A.
        • Horta B.
        • Anselmi L.
        • Araujo C.L.
        • et al.
        What are the causal effects of breastfeeding on IQ, obesity and blood pressure? Evidence from comparing high-income with middle-income cohorts.
        Int J Epidemiol. 2011; 40: 670-680
        • Gage S.H.
        • Davey Smith G.
        • Zammit S.
        • Hickman M.
        • Munafo M.R.
        Using Mendelian randomisation to infer causality in depression and anxiety research.
        Depress Anxiety. 2013; 30: 1185-1193
        • Schizophrenia Working Group of the Psychiatric Genomics Consortium
        Biological insights from 108 schizophrenia-associated genetic loci.
        Nature. 2014; 511: 421-427
        • Hickman M.
        • Vickerman P.
        • Macleod J.
        • Lewis G.
        • Zammit S.
        • Kirkbride J.
        • Jones P.
        If cannabis caused schizophrenia--how many cannabis users may need to be prevented in order to prevent one case of schizophrenia? England and Wales calculations.
        Addiction. 2009; 104: 1856-1861
        • Danovitch I.
        • Gorelick D.A.
        State of the art treatments for cannabis dependence.
        Psychiatr Clin North Am. 2012; 35: 309-326
        • Campbell R.
        • Starkey F.
        • Holliday J.
        • Audrey S.
        • Bloor M.
        • Parry-Langdon N.
        • et al.
        An informal school-based peer-led intervention for smoking prevention in adolescence (ASSIST): A cluster randomised trial.
        Lancet. 2008; 371: 1595-1602